AC Immune Targeting $50m IPO
Alzheimer's disease drug and vaccine developer AC Immune SA is aiming to raise $50m via an initial public offering that will take the company public on Nasdaq in the US. This follows a successful series E financing round in May this year that saw the company net $43.5m.
You may also be interested in...
Novan and AC Immune ended September with the first biopharma IPOs in 40 days as the performance of newly public companies’ stocks head into an upswing.
The two drug developers that managed to launch initial public offerings in the US during the past two weeks had to accept rough haircuts in order to get investors to buy their newly issued stock.
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.